ES2137981T3 - COMBINED TREATMENT BY ANTIMEDIATIC AND ANTIVIRIC AGENTS OF COMMON COLDS. - Google Patents
COMBINED TREATMENT BY ANTIMEDIATIC AND ANTIVIRIC AGENTS OF COMMON COLDS.Info
- Publication number
- ES2137981T3 ES2137981T3 ES93900648T ES93900648T ES2137981T3 ES 2137981 T3 ES2137981 T3 ES 2137981T3 ES 93900648 T ES93900648 T ES 93900648T ES 93900648 T ES93900648 T ES 93900648T ES 2137981 T3 ES2137981 T3 ES 2137981T3
- Authority
- ES
- Spain
- Prior art keywords
- years
- severity
- antiviric
- cold
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000009240 nasopharyngitis Diseases 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010001076 Acute sinusitis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000005141 Otitis Diseases 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000019258 ear infection Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 231100001251 short-term toxicity Toxicity 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL RESFRIADO COMUN Y LOS DESORDENES RELACIONADOS COMO GRIPE, SINUSITIS AGUDA, OTITIS AGUDA Y EXACERBACIONES INFECCIOSAS DE ENFERMEDAD PULMONAR OBSTRUSIVA SE TRATAN DE FORMA EFECTIVA SUMINISTRANDO UNA COMBINACION DE AGENTES ANTIVIRICOS Y COMPONENTES ANTIINFLAMATORIOS AL PACIENTE INFECTADO CON UN VIRUS DE GRIPE O RESFRIADO. UN AGENTE ANTIVIRICO Y DOS COMPONENTES ANTIINFLAMATORIOS SUMINISTRADOS A UN PACIENTE INFECTADO CON EL VIRUS DEL RESFRIADO REDUCE SIMULTANEAMENTE LA PROBABILIDAD DE DESARROLLAR UN RESFRIADO Y LA CANTIDAD Y DURACION DE LA EFUSION VIRICA Y DISMINUYE LA SEVERIDAD DE LOS SINTOMAS INDIVIDUALES DE RESFRIADO Y EL NUMERO TOTAL Y SEVERIDAD DE LOS SINTOMAS DEL RESFRIADO. COMPLEMENTANDO LA ACTIVIDAD DE LOS AGENTES ANTIVIRICOS Y ANTIINFLAMATORIOS COMBINADOS CON COMPONENTES TALES COMO ANTIHISTAMINAS Y AGONISTAS ALFA SE OBTIENEN BENEFICIOS NASALES SORPRENDENTEMENTE BUENOS. LA TERAPIA DE COMBINACION, DENOMINADA TERAPIA COVAM, SE TOLERA BIEN Y NO EVIDENCIA TOXICIDAD A CORTO PLAZO.THE COMMON COLD AND RELATED DISORDERS SUCH AS INFLUENZA, ACUTE SINUSITIS, ACUTE OTITIS AND INFECTIOUS EXACERBATIONS OF OBSTRUSIVE PULMONARY DISEASE ARE EFFECTIVELY TREATED BY PROVIDING A COMBINATION OF ANTIVIRIC AGENTS AND ANY COMPONENTS WITH ANTI-VIRUSING COMPONENTS. AN ANTI-VIRUS AGENT AND TWO ANTI-INFLAMMATORY COMPONENTS SUPPLIED TO A PATIENT INFECTED WITH THE VIRUS OF THE COLD SIMULTANEOUSLY REDUCE THE CHANCE OF DEVELOPING A COLD AND THE NUMBER AND DURATION OF THE VIRUS DISEASE AND YEARS OF THE SEVERITY OF THE YEARS OF THE YEARS OF THE SEVERITY AND THE SEVERITY OF THE YEARS AND THE SEVERITY OF THE YEARS AND THE SEVERITY OF THE YEARS AND THE SEVERITY OF THE YEARS AND DEVELOPMENT OF THE SYMPTOMS OF THE COLD. COMPLEMENTING THE ACTIVITY OF ANTIVIRIC AND ANTI-INFLAMMATORY AGENTS COMBINED WITH COMPONENTS SUCH AS ANTI-HISTAMINE AND ALPHA AGONISTS, YOU GET SURPRISINGLY GOOD NASAL BENEFITS. COMBINATION THERAPY, CALLED COVAM THERAPY, IS TOLERATED WELL AND DOES NOT EVIDENCE SHORT-TERM TOXICITY.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/794,520 US5240694A (en) | 1991-09-23 | 1991-11-19 | Combined antiviral and antimediator treatment of common colds |
| US82389192A | 1992-01-22 | 1992-01-22 | |
| PCT/US1992/010170 WO1993009764A1 (en) | 1991-11-19 | 1992-11-18 | Combined virustatic antimediator (covam) treatment of common colds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2137981T3 true ES2137981T3 (en) | 2000-01-01 |
Family
ID=27121512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93900648T Expired - Lifetime ES2137981T3 (en) | 1991-11-19 | 1992-11-18 | COMBINED TREATMENT BY ANTIMEDIATIC AND ANTIVIRIC AGENTS OF COMMON COLDS. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0661967B1 (en) |
| JP (1) | JPH08508007A (en) |
| AT (1) | ATE183640T1 (en) |
| CA (1) | CA2122719A1 (en) |
| DE (1) | DE69229880T2 (en) |
| ES (1) | ES2137981T3 (en) |
| WO (1) | WO1993009764A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492689A (en) * | 1991-11-19 | 1996-02-20 | The Center For Innovative Technology | Combined virustatic antimediator (COVAM) treatment of common colds |
| CA2227958A1 (en) * | 1995-07-28 | 1997-02-13 | Sekhar Mitra | Compositions containing analgesics and antihistamines and methods for treating respiratory disorders |
| IL131492A0 (en) * | 1997-04-30 | 2001-01-28 | Warner Lambert Co | Topical nasal antiinflammatory compositions |
| PL208686B1 (en) * | 2001-09-18 | 2011-05-31 | Nycomed Danmark Aps | Compositions for treatment of common cold |
| ES2235655B1 (en) * | 2003-12-29 | 2006-03-16 | Hartington Business, S.L. | ISOLATED EXTRACT FROM A CYCLAMEN EUROPAEUM L. PLANT AS A THERAPEUTIC AGENT. |
| DE102004049008A1 (en) | 2004-10-05 | 2006-04-06 | Merck Patent Gmbh | New use for α-sympathomimetics with 2-imidazoline structure |
| SE534514C2 (en) * | 2006-03-14 | 2011-09-20 | Wholesome Biopharm Pty Ltd | Composition for the treatment of allergic diseases |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US10130714B2 (en) * | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2885311B1 (en) | 2012-08-18 | 2020-01-01 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| KR102298172B1 (en) | 2013-09-06 | 2021-09-06 | 아카데미아 시니카 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| KR20160104727A (en) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | Compositions and methods for treatment and detection of cancers |
| TWI797430B (en) | 2014-03-27 | 2023-04-01 | 中央研究院 | Reactive labelling compounds and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR20240096599A (en) | 2014-05-27 | 2024-06-26 | 아카데미아 시니카 | Anti-cd20 glycoantibodies and uses thereof |
| AU2015267052A1 (en) | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
| JP7063538B2 (en) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | Anti-TNFα sugar-manipulated antibody group and its use |
| CN107001404B (en) | 2014-09-08 | 2021-06-29 | 中央研究院 | Activation of human iNKT cells using glycolipids |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| TWI736523B (en) | 2015-01-24 | 2021-08-21 | 中央研究院 | Novel glycan conjugates and methods of use thereof |
| CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
| AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269842A (en) * | 1979-12-05 | 1981-05-26 | Rhone-Poulenc Industries | Method for treating rhinoviral complaints |
| EP0311616B1 (en) * | 1986-06-17 | 1991-09-25 | Biogen, Inc. | Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases |
| US5137876A (en) * | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
-
1992
- 1992-11-18 JP JP5509566A patent/JPH08508007A/en not_active Ceased
- 1992-11-18 DE DE69229880T patent/DE69229880T2/en not_active Expired - Fee Related
- 1992-11-18 ES ES93900648T patent/ES2137981T3/en not_active Expired - Lifetime
- 1992-11-18 AT AT93900648T patent/ATE183640T1/en not_active IP Right Cessation
- 1992-11-18 CA CA002122719A patent/CA2122719A1/en not_active Abandoned
- 1992-11-18 EP EP93900648A patent/EP0661967B1/en not_active Expired - Lifetime
- 1992-11-18 WO PCT/US1992/010170 patent/WO1993009764A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69229880D1 (en) | 1999-09-30 |
| EP0661967A1 (en) | 1995-07-12 |
| EP0661967B1 (en) | 1999-08-25 |
| DE69229880T2 (en) | 2000-05-04 |
| CA2122719A1 (en) | 1993-05-27 |
| JPH08508007A (en) | 1996-08-27 |
| EP0661967A4 (en) | 1994-09-29 |
| ATE183640T1 (en) | 1999-09-15 |
| WO1993009764A1 (en) | 1993-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2137981T3 (en) | COMBINED TREATMENT BY ANTIMEDIATIC AND ANTIVIRIC AGENTS OF COMMON COLDS. | |
| BR9913157A (en) | Processes for treating or preventing infection caused by at least one virus of the flaviviridae and diseases associated with said infection and infection caused by at least one virus of the genus hepacivirus of flavivirity and diseases associated with said infection, pharmaceutical composition to treat or prevent viral infections , it's composed | |
| Meltzer et al. | Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo | |
| TR200002739T2 (en) | Xylitol compositions in the treatment of upper respiratory problems | |
| BR0312286A (en) | 2 'and 3' prodrugs - modified nucleoside for treatment of flaviviridae infections | |
| YU7296A (en) | Novel pharmaceutical combination containing antivirus substance and one anti-inflamatory glucocorticoid | |
| BR9711086A (en) | Anti-myocrobial treatment for herpes simplex virus and other infectious diseases. | |
| KR960700742A (en) | ATOPIC DISEASE REMEDY | |
| ES2061453T3 (en) | ANTIVIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING HYPERICIN OR PSEUDOHIPERICINA. | |
| DE69731610D1 (en) | ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID | |
| NO20051987L (en) | Treatment of fungal infections. | |
| GT199900015A (en) | PROCEDURE TO TREAT HEART FAILURE | |
| BR0107628A (en) | 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation | |
| BR9803233A (en) | Preparation of a pharmaceutical combination of a sodium / hydrogen exchanger inhibitor and a drug for the treatment of cardiovascular diseases. | |
| Zhou et al. | Pyrogallol protects against influenza A virus‐triggered lethal lung injury by activating the Nrf2–PPAR‐γ–HO‐1 signaling axis | |
| HUP0200152A2 (en) | Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites | |
| CL2022001102A1 (en) | Methods for the treatment of depressive disorders. | |
| BR112021024001A2 (en) | Broad spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of use thereof | |
| BR0310061A (en) | Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions | |
| DE59710517D1 (en) | ADAMANTANAMINE DERIVATIVES FOR CONTROLLING VIRUSES OF THE BORNAVIRIDAE FAMILY | |
| ES2191662T3 (en) | USE OF A POLYHYDROXI-BENZAMIDE OR ONE OF ITS DERIVATIVES IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF VIRAL INFECTIONS. | |
| MX2021010834A (en) | Compound and method for the prevention of transmission of influenza virus. | |
| ATE81462T1 (en) | GLYCOSAMINOGLYCAN FOR THE TREATMENT OF DIABETIC MICROANGIOPATHIA. | |
| RU94016333A (en) | DRUG FOR THE TREATMENT OF VIRAL DISEASES | |
| EA200400535A1 (en) | SUPPRESSION OF VIRUSES N-DOCOSANOL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 661967 Country of ref document: ES |